A 74-year-old woman is evaluated in the clinic following a recent non-traumatic T12 verteb… — USMLE Step 3

A $74$ -year-old woman is evaluated in the clinic following a recent non-traumatic T12 vertebral compression fracture. A dual-energy x-ray absorptiometry (DEXA) scan reveals a T-score of $-3.2$ at the lumbar spine and $-2.9$ at the femoral neck. Her medical history includes type 2 diabetes mellitus, hypertension, and chronic kidney disease. Five years ago, she developed a provoked deep vein thrombosis following orthopedic surgery. Twelve years ago, she underwent lumpectomy followed by localized external beam radiation therapy for early-stage right breast cancer. Current medications include amlodipine, metformin, and cholecalciferol.

Vital signs are within normal limits. Laboratory studies are as follows:

Test	Result	Reference Range
Serum calcium	$9.2$ mg/dL	$8.4-10.2$ mg/dL
Serum phosphorus	$3.8$ mg/dL	$2.7-4.5$ mg/dL
25-hydroxyvitamin D	$38$ ng/mL	$20-50$ ng/mL
Intact parathyroid hormone	$55$ pg/mL	$15-65$ pg/mL
Estimated glomerular filtration rate	$22$ mL/min/ $1.73\text{m}^2$	$> 90$ mL/min/ $1.73\text{m}^2$

Which of the following is the most appropriate pharmacologic intervention to reduce this patient's risk of future fractures?

Subcutaneous denosumabAnswer
B
Oral alendronate
C
Intravenous zoledronic acid
D
Subcutaneous teriparatide
E
Oral raloxifene

Answer

Subcutaneous denosumab is the most appropriate and safest pharmacologic intervention for this patient's severe osteoporosis, given her multiple comorbidities.

The correct answer is subcutaneous denosumab. This patient has severe osteoporosis, as evidenced by a fragility fracture and a T-score of

-3.2

, requiring immediate pharmacologic intervention. However, her complex medical history restricts her treatment options. She has chronic kidney disease stage 4 with an eGFR of

22

mL/min/

1.73\text{m}^2

. Bisphosphonates (both oral and intravenous) are renally cleared and are strictly contraindicated in patients with an eGFR

< 35

mL/min/

1.73\text{m}^2

due to the risk of systemic accumulation, excessive suppression of bone turnover, and acute renal toxicity. Her history of external beam radiation therapy is an absolute contraindication to teriparatide due to a dose-dependent increased risk of osteosarcoma. Furthermore, her history of provoked deep vein thrombosis contraindicates the use of raloxifene, a selective estrogen receptor modulator that carries a black-box warning for venous thromboembolism. Denosumab is a monoclonal antibody against RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). It is degraded by the reticuloendothelial system rather than the kidneys, making it the preferred and safest agent for treating osteoporosis in patients with severe renal impairment. It does not increase the risk of osteosarcoma or venous thrombosis. Because denosumab can cause significant hypocalcemia, confirming normal serum calcium and vitamin D levels prior to initiation is essential, which this patient has already met.

Step-by-Step Solution

Evaluate the indication for therapy.

The patient has severe osteoporosis, confirmed by a T-score of

-3.2

and a fragility fracture, requiring prompt pharmacologic treatment.

Establishing the baseline need for therapy is the first step before filtering options based on comorbidities.

Analyze renal function against medication safety profiles.

The patient has chronic kidney disease stage 4 (eGFR

22

mL/min/

1.73\text{m}^2

). This definitively rules out both oral and intravenous bisphosphonates.

Renally cleared bisphosphonates can accumulate and cause adynamic bone disease or direct renal toxicity when eGFR is

< 35

mL/min/

1.73\text{m}^2

Assess the impact of oncologic history.

The history of localized external beam radiation therapy absolutely contraindicates the use of teriparatide.

Teriparatide carries a dose-dependent increased risk of osteosarcoma, particularly in irradiated bone.

Assess the impact of vascular history.

The history of provoked deep vein thrombosis contraindicates the use of raloxifene.

Raloxifene, a selective estrogen receptor modulator, significantly increases the risk of venous thromboembolism.

Select the remaining safe and effective agent.

Denosumab effectively treats osteoporosis and is safe to use. Her normal calcium, phosphorus, and vitamin D levels ensure she is optimized to begin this therapy.

Denosumab is degraded by the reticuloendothelial system, not the kidneys, and avoids the specific contraindications associated with her other comorbidities.

Key Concept

Identifying absolute and relative contraindications for osteoporosis medications (bisphosphonates in severe CKD, teriparatide with prior radiation, SERMs with prior VTE) to select the safest pharmacologic intervention.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic